{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096191","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.918504+00:00","generated_at":"2026-05-31T09:44:12.196345+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bolt Biotherapeutics Q2 2024 loss from operations $22.6M; cash $97.5M, BDC-3042 advances to Cohort 6","bullets":["Loss from operations of $22.6M for Q2 2024 vs $19.8M in Q2 2023; restructuring charges of $3.6M.","Cash, cash equivalents and marketable securities of $97.5M as of June 30, 2024; runway through mid-2026.","BDC-3042 Phase 1 advanced to Cohort 6; no dose-limiting toxicities in Cohort 5.","BDC-4182 (claudin 18.2-targeting ISAC) abstract accepted at SITC 2024; IND-enabling activities ongoing.","Collaboration revenue $1.3M; R&D expenses $15.4M; G&A expenses $4.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096191","json":"https://secwatch.observer/filing/0000950170-24-096191.json","markdown":"https://secwatch.observer/filing/0000950170-24-096191.md","text":"https://secwatch.observer/filing/0000950170-24-096191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000095017024096191/0000950170-24-096191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000095017024096191/bolt-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:44:12.196345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}